摘要:目的: 系統評價非布索坦治療痛風的療效及安全性。 方法 :計算機檢索PubMed、EMBASE、SCI、CBM、CNKI、VIP、萬方數據庫及Cochrane圖書館,手工補充檢索;納入非布索坦治療痛風的隨機對照試驗(RCT);進行方法學質量評價和Meta分析。 結果 :共納入3個RCT(受試者1985例),A級文獻1篇,B級文獻2篇。Meta分析結果顯示:最后3月血清尿酸(SU)持續低于60 mg/dl患者數、隨訪結束時SU低于60 mg/dl患者數非布索坦組與對照組差異均有統計學意義;治療相關不良事件發生數與安慰劑組差異無統計學意義,與別嘌呤組差異有統計學意義。 結論 :基于當前證據,非布索坦治療痛風,能有效降低SU含量,減少治療相關不良事件發生率。Abstract: Objective: Assessing the effectiveness and safety of febuxostat for the treatment of gout. Methods :Randomized controlled trails(RCT) of febuxostat for the treatment of gout were gathered from the Cochrane Library、PubMed、EMBASE、SCI、CBM、CNKI、VIP、Wangfang Database, other relative researches were handsearched, each RCT was methodological quality evaluated, then analyzed by software RevMan50 Results :A total of 3 RCTs were collected (involving 1985 subjects); 1 was graded A, 2 were B; according to the Metaanalysis: the differences of subjects with last 3 monthly serum urate(SU)<60mg/dl and subjects with SU<60mg/dl at final visits were significant; treatmentrelated adverse events between febuxostat and allopurinol was significant different, but not significant difference between febuxostat and placebo. Conclusion : According to the evidence currently, febuxostat could reduce SU and the episodes of treatmentrelated adverse events.
【摘要】 目的 分析吲哚美辛栓所致不良反應的臨床特征、相關因素,為臨床藥物治療中藥品不良反應的防治提供參考依據。方法 檢索1986年—2009年中國生物醫學文獻系統吲哚美辛栓的不良反應資料,并加以分析研究。結果 得到符合標準的患者24例,不良反應報告中男性多于女性;不良反應以全身性損害最多(12例,50.00%),其次為皮膚及附件損害(2例,8.33%)、循環系統損害(2例,8.33%)、消化系統損害(2例,8.33%);不良反應較為嚴重。結論 患者的年齡、性別等因素能影響不良反應的發生,臨床應特別注意吲哚美辛栓引起的休克。
ObjectiveTo study the techniques of mimicking multifactors induced acute pancreatitis in rat by slow-release pump. MethodsSeventy-five healthy SD rats were randomly divided into slowrelease pump group (SRP group), traditional group (TAP group), and sham operation group (SO group). Four percent sodium taurocholate was injected through pancreatobiliary duct of rats directly and retrogradely in TAP group and by slow-release pump in SRP, which mimicked AP pathogenesis from selfdigestion, obstruction, cytokine activation, and many other mechanisms. Detection of serum amylase and pancreatic myeloperoxidase (MPO) leves, observation of pancreatic histological changes and scoring of pancreatitis severity in three groups were performed at 1, 6, 12, and 24 h after successful model induction, respectively. ResultsSerum amylase and pancreatic MPO levels, and the pathological grading score of rats were significantly higher in SRP and TAP groups than in SO group at different time point (Plt;0.05 or Plt;0.01), while they were lower in SRP group than in TAP group with a slowly rising tendency, and there were significant differences at 6 and 12 h time point, respectively (Plt;0.05 or Plt;0.01). Conclusions Slow-release pump technique can induce AP through increasing the pressure of pancreatic duct, tissue edema and sustained releasing inflammation factors by mimicking the pathophysiological process of pancreatitis. Slow-release pump can be kept in place to monitor and control the pressure of pancreatic duct. Slow-release pump method is relatively moderate and easy to manage with a lower mortality.